Invivyd (IVVD): Assessing Valuation After S&P Biotechnology Select Industry Index Inclusion [Yahoo! Finance]
Invivyd, Inc. (IVVD)
Company Research
Source: Yahoo! Finance
See our latest analysis for Invivyd. That index inclusion lands on top of a powerful run, with the share price closing at $2.88 and a 90 day share price return of 148.28 percent that caps a striking 500 percent year to date share price return, while the 1 year total shareholder return of 511.34 percent suggests that momentum has been building as investors reassess both growth potential and risk. If Invivyd's surge has caught your eye, it could be a good moment to explore other biotech names via healthcare stocks and see what else is building similar momentum. With the stock already up several hundred percent and still trading at a steep discount to analyst targets, investors now face a key question: Is Invivyd undervalued, or is the market already pricing in its future growth? With Invivyd last closing at $2.88 versus a narrative fair value of $10.00, the gap points to a potentially dramatic rerating if assumptions hold. The transition to a fully internalized, best in class
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVIDGlobeNewswire
- Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVIDGlobeNewswire
- Invivyd (NASDAQ:IVVD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.MarketBeat
- How Recent Clinical Progress Is Rewriting the Story for Invivyd [Yahoo! Finance]Yahoo! Finance
- Invivyd (NASDAQ:IVVD) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
IVVD
Earnings
- 11/6/25 - Miss
IVVD
Sec Filings
- 12/23/25 - Form 8-K
- 12/19/25 - Form S-3/A
- 11/25/25 - Form SCHEDULE
- IVVD's page on the SEC website